About Nuo Therapeutics
Nuo Therapeutics is a company based in Gaithersburg (United States) founded in 2001.. Nuo Therapeutics has raised $69.12 million across 18 funding rounds from investors including MidCap Financial, Anson Group and Maryland Department of Commerce. The company has 9 employees as of December 31, 2024. Nuo Therapeutics has completed 2 acquisitions, including Aldagen and Angel Systems. Nuo Therapeutics offers products and services including Aurix. Nuo Therapeutics operates in a competitive market with competitors including Adocia, Imbed Biosciences, Cresilon, Ilya Pharma and QBiotics, among others.
- Headquarter Gaithersburg, United States
- Employees 9 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology Aerospace, Defense & Maritime
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Nuo Therapeutics, Inc.
-
Annual Revenue
$1.37 M124.34as on Dec 31, 2024
-
Net Profit
$-2.32 M26.73as on Dec 31, 2024
-
EBITDA
$-2.36 M22.9as on Dec 31, 2024
-
Total Equity Funding
$69.12 M (USD)
in 18 rounds
-
Latest Funding Round
$791.42 K (USD), Post-IPO
Jul 30, 2025
-
Investors
MidCap Financial
& 3 more
-
Employee Count
9
as on Dec 31, 2024
-
Investments & Acquisitions
Aldagen
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Nuo Therapeutics
Nuo Therapeutics is a publicly listed company on the OTC with ticker symbol AURX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Nuo Therapeutics
Nuo Therapeutics offers a comprehensive portfolio of products and services, including Aurix. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Biodynamic hematogel using patient's platelets for wound healing.
Funding Insights of Nuo Therapeutics
Nuo Therapeutics has successfully raised a total of $69.12M across 18 strategic funding rounds. The most recent funding activity was a Post-IPO round of $791.42 thousand completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 18
- Last Round Post-IPO — $791,418
-
First Round
First Round
(22 Apr 2010)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2025 | Amount | Post-IPO - Nuo Therapeutics | Valuation |
investors |
|
| Sep, 2024 | Amount | Post-IPO - Nuo Therapeutics | Valuation |
investors |
|
| May, 2024 | Amount | Post-IPO - Nuo Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Nuo Therapeutics
Nuo Therapeutics has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include MidCap Financial, Anson Group and Maryland Department of Commerce. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private debt funds are managed across multiple sectors.
|
Founded Year | Domain | Location | |
|
Diversified operations are conducted across multiple industries by Anson Group.
|
Founded Year | Domain | Location | |
|
Government agency focused on development of Maryland
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Nuo Therapeutics
Nuo Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Aldagen and Angel Systems. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Regenerative cell therapies for vascular disorders
|
2001 | ||||
|
Provider of pest control services
|
1988 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Nuo Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nuo Therapeutics Comparisons
Competitors of Nuo Therapeutics
Nuo Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adocia, Imbed Biosciences, Cresilon, Ilya Pharma and QBiotics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| domain | founded_year | HQ Location |
Nanotech-based wound care products are developed and provided.
|
|
| domain | founded_year | HQ Location |
Developer of hemostatic products for wound care
|
|
| domain | founded_year | HQ Location |
Biological drugs for skin and mucosa wound treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules from plant extracts are developed for medical applications.
|
|
| domain | founded_year | HQ Location |
Enzymatic therapies for tissue repair and regeneration are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Nuo Therapeutics
Frequently Asked Questions about Nuo Therapeutics
When was Nuo Therapeutics founded?
Nuo Therapeutics was founded in 2001 and raised its 1st funding round 9 years after it was founded.
Where is Nuo Therapeutics located?
Nuo Therapeutics is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Who is the current CEO of Nuo Therapeutics?
David Jorden is the current CEO of Nuo Therapeutics.
Is Nuo Therapeutics a funded company?
Nuo Therapeutics is a funded company, having raised a total of $69.12M across 18 funding rounds to date. The company's 1st funding round was a Post-IPO of $650.88K, raised on Apr 22, 2010.
How many employees does Nuo Therapeutics have?
As of Dec 31, 2024, the latest employee count at Nuo Therapeutics is 9.
What is the annual revenue of Nuo Therapeutics?
Annual revenue of Nuo Therapeutics is $1.37M as on Dec 31, 2024.
What does Nuo Therapeutics do?
Founded in 2001 and based in Gaithersburg, United States, regenerative products targeting wound care, inflammation, and angiogenesis are developed by the company. Operations center on autologous platelet and plasma therapies, with the proprietary Aurix systema biodynamic hematogelapproved by the FDA for managing wounds and ulcers of varying types and severities. Focus remains on advancing therapies within the biotechnology sector.
Who are the top competitors of Nuo Therapeutics?
Nuo Therapeutics's top competitors include Imbed Biosciences, Adocia and Ilya Pharma.
What products or services does Nuo Therapeutics offer?
Nuo Therapeutics offers Aurix.
Is Nuo Therapeutics publicly traded?
Yes, Nuo Therapeutics is publicly traded on OTC under the ticker symbol AURX.
How many acquisitions has Nuo Therapeutics made?
Nuo Therapeutics has made 2 acquisitions, including Aldagen, and Angel Systems.
Who are Nuo Therapeutics's investors?
Nuo Therapeutics has 4 investors. Key investors include MidCap Financial, Anson Group, Maryland Department of Commerce, and Aldagenholdings.
What is Nuo Therapeutics's ticker symbol?
The ticker symbol of Nuo Therapeutics is AURX on OTC.